Overview

First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors

Status:
Recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
This is the first-in-human study of 68Ga/64Cu-FAPI-XT117, which is an prospective, single-arm phase I clinical study.
Phase:
Phase 1
Details
Lead Sponsor:
Chinese PLA General Hospital
Collaborator:
Sinotau Pharmaceutical Group